PHOTO
Dubai –The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to announce their partnership with the Saudi Society for Blood Disorders in the development of the GCC’s first online resource for blood cancer information to be available in Arabic.
Salamat Damak – salamatdamak.com - is the first online blood cancer information resource to be available in Arabic in the Arabian Gulf. The web-based platform, developed by the Saudi Society for Blood Disorders and sponsored by Janssen, seeks to provide credible medical information about blood diseases for patients and their families in the GCC. All content of Salamat Damak has been developed by the scientific committee of the site.
The Saudi Society for Blood Disorders was established to lead and influence the practice of hematology in Saudi Arabia through the promotion of excellence in patient care, research, continuous professional and public education. It has a mission to act as a resource for patients and workers in the field of specialization and provide social and psychological support to patients and their families.
Blood cancers comprise approximately seven percent of all cancers diagnosed worldwide[1]. There are many types of blood cancer. Each has different symptoms, treatments and prognoses. The main three types of blood cancers are leukemia, lymphoma, and myeloma. These three types affect around 8000 patients each year in the Gulf and historically there has been little information or resources available to those whose lives are affected by them. The Salamat Damak site is part of a shared regional vision to improve and enhance the quality of healthcare services and provide world-class healthcare infrastructure for a healthier population.
Dr. Feras Alfraih, President of Saudi Society for Blood Disorders, said: “We are delighted to launch Salamat Damak as a rich education and information resource for blood cancer patients and their families in the GCC. We firmly believe that well-informed patients have better treatment outcomes than less-informed patients and in developing Salamat Damak in conjunction with our partners across the region, we have sought to bring together a range of accredited resources that provide practical information and direction on psychological and social support to blood cancer patients across the region”.
Dr. Feras Alfraih, continued: “Salamat Damak is the first online platform in Arabic for the public focusing on blood diseases. It offers a range of services including ask a doctor, share your inspiring story and numerous medical resources for patients and their families. Saudi Society for Blood Disorders values the partnership with Janssen on this pioneering project.”
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
